Pioneering Off the Shelf, Allogeneic T‑Cell Immunotherapies
At Atara, our mission is to transform the lives of patients with serious diseases through pioneering science, teamwork and a commitment to excellence. We aim to offer hope to people whose lives have been impacted by cancer and autoimmune diseases.
Leveraging our novel allogeneic EBV T-cell platform, Atara intends to deliver treatments to patients with high unmet medical need.
Our platform aims to leverage the unique biology of EBV T cells to channel the power of the immune system and has the potential to treat a wide range of diseases.
Atara is applying this one platform with no gene editing of the T-cell receptor to create a robust pipeline with the goal of developing treatments that improve the quality and longevity of patients' lives.
Key Features of Atara’s EBV T-Cell Platform
EBV T cells
EBV T cells naturally possess the following key characteristics:
- Trafficking to the site of the disease
- Specificity for disease targets with a low likelihood to harm normal cells
- Ability to persist in the body long enough to fight disease
Allogeneic Donor Cells
Cells from donors are manufactured and stored in inventory with the goal of being readily available for patients with serious diseases
Next-Generation CAR T Technologies
Next-generation technologies designed to:
- Improve persistence
- Decrease cell exhaustion and death
- Overcome the hostile tumor microenvironment
- Target solid tumors
T-Cell Manufacturing and Delivery Platform
- Robust, scalable manufacturing process
- World-class facility
- Designed for rapid delivery to patients within 3 days
- Biologics-like cost-of-goods profile
A Differentiated Approach to Allogeneic Cell Therapy, with No Gene Editing of the T-Cell Receptor
Robust Allogeneic T-Cell Immunotherapy Pipeline
Three Strategic Priorities
World-Class T-cell Research & Development Capabilities and Manufacturing Technologies
Atara’s manufacturing technology is robust and designed to meet global regulatory standards and rapidly deliver products to patients from inventory within three days, with commercial validation activities near completion.
The Atara Research Center (ARC) houses the Company’s Translational and Pre-Clinical Sciences, Process Sciences, and Analytical Development teams. Its dedicated capabilities support our product pipeline and help drive innovation by leveraging our differentiated allogeneic cell therapy platform.
Our Fitzsimons facility in Denver is our hub for Process Development and Quality Control, with its capabilities facilitating the development, scale up, tech transfer and optimization of Atara’s advanced manufacturing processes for allogeneic cell therapies. In addition, select lot release testing of Atara’s drug products are performed at the site.